Genetron Health to Announce Third Quarter Unaudited Financial Results and Host Investor Call on November 9, 2020
October 26 2020 - 8:00AM
Genetron Holdings Limited (“Genetron Health” or the “Company”,
NASDAQ:GTH), a leading precision oncology platform company in China
that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced that that it will report unaudited financial
results for the third quarter ended September 30, 2020 on November
9, 2020 before the US market open.
Management will host a conference call for
investors at 8:30 a.m. ET (9:30 p.m. Beijing time) on Monday,
November 9, 2020. The conference call can be accessed by dialing
the following numbers:
United States: |
+1-845-675-0437 |
China Domestic: |
400-620-8038 |
Hong Kong: |
+852-3018-6771 |
International: |
+65-6713-5090 |
Conference ID: |
5248398 |
Participants are encouraged to dial into the
call at least 15 minutes in advance due to high call volumes.
A replay will be accessible through December 9,
2020, by dialing the following numbers:
United States: |
+1-855-452-5696 |
International: |
+61-2-8199-0299 |
Conference ID: |
5248398 |
A simultaneous webcast of the conference call
will be available on the "News and Events" page of the Investors
section of the Company's website. A replay of the webcast will be
available for 30 days following the event. For more information,
please visit ir.genetronhealth.com.
About Genetron Holdings
Limited
Genetron Holdings Limited (“Genetron Health” or
the “Company”) (Nasdaq:GTH) is a leading precision oncology
platform company in China that specializes in cancer molecular
profiling and harnesses advanced technologies in molecular biology
and data science to transform cancer treatment. The Company has
developed a comprehensive oncology portfolio that covers the entire
spectrum of cancer management, addressing needs and challenges from
early screening, diagnosis and treatment recommendations, as well
as continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking
statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Statements that are not historical facts, including
statements about the Company’s beliefs and expectations, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and a number of factors could
cause actual results to differ materially from those contained in
any forward-looking statement. In some cases, forward-looking
statements can be identified by words or phrases such as “may”,
“will,” “expect,” “anticipate,” “target,” “aim,” “estimate,”
“intend,” “plan,” “believe,” “potential,” “continue,” “is/are
likely to” or other similar expressions. Further information
regarding these and other risks, uncertainties or factors is
included in the Company’s filings with the SEC. All information
provided in this press release is as of the date of this press
release, and the Company does not undertake any duty to update such
information, except as required under applicable law.
Investor Relations ContactsUS:Hoki LukHead of
Investor RelationsEmail: hoki.luk@genetronhealth.com Phone: +1
(408) 204-5343
Stephanie CarringtonWestwicke, an ICR CompanyEmail:
Stephanie.Carrington@westwicke.com Phone: +1 (646)
277-1282
Asia:Bill ZimaICR, Inc.Email:
bill.zima@icrinc.com GenetronIR@icrinc.com
Media Relations ContactEdmond
LococoICREdmond.Lococo@icrinc.com Mobile: +86
138-1079-1408genetron.pr@icrinc.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024